The Effect of NovoMix® 30, Levemir® or NovoRapid® (Alone or in Combination) in Subjects With Type 2 Diabetes Previously Treated With Other Anti-diabetic Medication. A 24-week, International, Prospective, Multi-centre, Open-labelled, Non-interventional Study

CompletadoClinicalTrials.gov

ID: NCT00869908Tipo: OBSERVATIONALInicio: 1 de nov de 2008Fin estimado: 1 de mar de 2011

Traducción no disponible, mostrando original

Resumen

This study is conducted in Africa, Asia, South America and Europe. The aim of this observational study is to document the experience with the study insulins when used in routine clinical practice. After the physician's decision to start insulin treatment using NovoMix® 30, Levemir® or NovoRapid® (alone or combined), type 2 diabetics will be eligible to be included in this study at the physician's discretion

Elegibilidad

Sexo: ALL

Criterios de inclusión

After the physician has taken the decision to use NovoMix®30, Levemir® or NovoRapid® (alone or combined), any subject with type 2 diabetes who is not treated with these insulins or who has started on these insulin within the last 4 weeks before inclusion into this study is eligible for the study.
The selection of the subjects will be at the discretion of the individual physician.

Criterios de exclusión

Subjects treated with NovoMix® 30, Levemir® or NovoRapid® (alone or in combination) for more than 4 weeks before inclusion into this study.
Subjects who were previously enrolled in this study.
Subjects with a hypersensitivity to NovoMix® 30, Levemir® or NovoRapid® or to any of the excipients.
Women who are pregnant, breast feeding or have the intention of becoming pregnant within the next 6 months.

Intervenciones

drug

insulin aspart

Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation

drug

insulin detemir

Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation

drug

biphasic insulin aspart

Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation

Ubicaciones

Novo Nordisk Investigational Site

Prov. de Buenos Aires, Argentina

Patrocinadores

PrincipalNovo Nordisk A/S

Aviso: La información de este ensayo proviene de fuentes públicas y tiene carácter exclusivamente informativo. No constituye asesoramiento médico, regulatorio ni de ningún otro tipo. Las traducciones son automatizadas y no poseen validez oficial. Consultá siempre con un profesional de la salud. Ver Términos de Uso.

The Effect of NovoMix® 30, Levemir® or NovoRapid® (Alone ... | EligiMed